Australia markets closed

INmune Bio, Inc. (INMB)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
19.19+0.39 (+2.07%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close18.80
Open18.68
Bid0.00 x 1100
Ask0.00 x 3000
Day's range18.68 - 19.76
52-week range7.28 - 30.37
Volume88,185
Avg. volume449,343
Market cap342.382M
Beta (5Y monthly)2.85
PE ratio (TTM)N/A
EPS (TTM)-1.37
Earnings date03 Nov 2021 - 08 Nov 2021
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est32.75
  • GlobeNewswire

    INmune Bio, Inc. to Participate in the B. Riley Fall 2021 Best Ideas in Oncology Series

    Boca Raton, FL, Sept. 27, 2021 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the, “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, today announced that Mark Lowdell, PhD, Chief Scientific Officer and Chief Medical Officer, will be participating in an oncology panel at the B. Riley Fall 2021 Best Ideas in Oncology Series. Panel details: Title: Improving Strategies to Harness the Immune System

  • GlobeNewswire

    INmune Bio, Inc. Announces Participation at Upcoming Investor Conferences

    BOCA RATON, Florida, Sept. 20, 2021 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, today announced that Raymond J. Tesi, MD, President and CEO, is scheduled to participate in two upcoming investor conferences in September 2021. Oppenheimer Fall Healthcare Life Sciences & MedTech SummitPresentation Date: Wednesday, September 22Presentation Ti

  • Zacks

    INmune (INMB) Announces Positive Data for its AD Candidate

    INmune Bio (INMB) announces positive data for its AD candidate, XPro, from an early stage study. Shares are up in pre-market.